Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: Patentlawmeister who wrote (4320)	11/19/2003 4:50:33 PM
From: PuddleGlum	Respond to of 37387

I put in a sell order several days ago at 1.35 for part of my DRUG position. It touched that level twice, but my shares weren't taken. Now it's a real long term hold :-(. Volume wasn't very convincing today, certainly not what one would expect for a 20% decline, so you're probably correct about this being an uneducated overreaction. The bad news is that some technical damage was done today. GORX also failed (so far) on its breakout. CAMY is quietly ascending, however, and it's probably a good idea to add to that one.

To: Patentlawmeister who wrote (4320)	11/19/2003 5:27:03 PM
From: Guy.	Respond to of 37387

Cuda, i can understand that reaction to DRUG's 10Q. People are expecting to see larger revenues and even a little profit. DRUG shows the same level of revenues for too long. The market is huge and they need to capture a larger part of it. They had lots of time. I believe in them, but they need to move their a$$. I don't own any shares right now so i don't mind DRUG falling to .50 so i can collect some...

To: Patentlawmeister who wrote (4320)	11/19/2003 7:18:44 PM
From: Sleepman	Respond to of 37387

I agree that this looks like an overreaction. I totally agree with your assessment of the revenues. I too would like to see more intrinsic growth in nonpatent countries, but the real story with Dragon is going to play out over the next 2 years as they prepare to move into Europe and Japan when patents there expire. The report indicated that they are making definite steps in that direction. Their current CEO is from a European drug conglomerate and he will be well connected to see this through. It sounds like they are updating their technology to be a step above the typical low cost producer. I have to explore this a little more with the company, but it sounds positive to me. They still have a steady cash flow going with what they are doing and should be able to expand using that as a base. Time will tell.